Abstract:There is a continuing, urgent need for an ophthalmic (eye) drop for the clinical therapy of age-related macular degeneration (AMD), a leading cause of blindness. Here, we report the first formulation of an eye drop that is effective via autophagy for AMD treatment. This eye drop is based on a single natural product derivative (ACD), which is an amphiphilic molecule containing a 6-aminohexanoate group (H2N(CH2)5COO−). We demonstrate that this eye drop reverses the abnormal angiogenesis induced in a primate model of AMD that has the pathological characteristics close to that of human AMD. The ACD molecule was self-assembled in an aqueous environment leading to nanoparticles (NPs) about 9.0 nm in diameter. These NPs were encapsulated in calcium alginate hydrogel. The resulting eye drop effectively slowed the release of ACD and displayed extended release periods in both simulated blood (pH 7.4) and inflammatory (pH 5.2) environments. We show that the eye drop penetrated both the corneal and blood–eye barriers and reached the fundus. With low cellular toxicity, the drop targeted S1,25D3-membrane-associated rapid response steroid-binding protein (1,25D3-MARRS) promoting autophagy in a dose-dependent manner. In addition, the drop inhibited cell migration and tubular formation. On the other hand, when protein 1,25D3-MARRS was knocked down, the eye drop did not exhibit such inhibition functionalities. Our study indicates that the 6-aminohexanoate group on self-assembled NPs encapsulated in hydrogel leads to the positive in vivo outcomes. The present formulation offers a promising approach for clinical treatment of human AMD.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acsami.0c17296?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsami.0c17296</a>.Experimental methods; inflammatory infiltration prevented in the AMD monkey model (Figure S1-1); comparison of the antichoroidal neovascularization activity (CNV) (Figure S1-2); estimation of the eye injury for the two groups (shown in <a class="internalNav" href="#fig1">Figure </a><a class="internalNav" href="#fig1">1</a>) (Table S1); preparation and characterization of eye drops (Figure S2-1); measurements of ACD nanoparticle size up to 21 days (Figure S2-2); exploration of the self-assembly of five Dio derivatives in water (Figure S2-3); investigation of the self-assembly of ACD in water (Figure S2-4); examination of the self-assembly of ACD in water containing five amounts of β-cyclodextrin (Figure S2-5); comparison of the release of ACD shown in <a class="internalNav" href="#fig3">Figure </a><a class="internalNav" href="#fig3">3</a> (Figure S3); pharmacokinetic studies of ACD in rats' plasma (Figure S4); summary of pharmacokinetic data for plasma ACD in rats (Table S2); optical microscope images for <a class="internalNav" href="#fig5">Figure </a><a class="internalNav" href="#fig5">5</a>a (Figure S5-1); in vivo toxicity study (Figure S5-2); exploration of the amount effect of EDTA calcium (Figure S5-3); quantitative analysis of LC3II/LC3I for <a class="internalNav" href="#fig6">Figure </a><a class="internalNav" href="#fig6">6</a>a Western blots (Figure S6-1); RPE cell explored for 1,25D3-MARRS and autophagy (Figure S6-2); quantitative analysis for <a class="internalNav" href="#fig7">Figures </a><a class="internalNav" href="#fig7">7</a>b,c (Figure S7); and note on the design and preparation of ACD eye drops (<a class="ext-link" href="/doi/suppl/10.1021/acsami.0c17296/suppl_file/am0c17296_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

Antioxidant and anti-glycated TAT-modified platinum nanoclusters as eye drops for non-invasive and painless relief of diabetic cataract in rats

Autoregenerative redox nanoparticles as an antioxidant and glycation inhibitor for palliation of diabetic cataracts

Facile fabrication of redox nanoparticles loaded with exosomal-miRNAs and resveratrol as glycation inhibitor in alleviating the progression and development of diabetic cataract

Potential of CeCl 3 @msio 2 Nanoparticles in Alleviating Diabetic Cataract Development and Progression

Preventive Effect of Astaxanthin on Diabetic Cataracts and Its Protective Effect on Lens Epithelial Cells

Tat PTD-Endostatin-RGD: A novel protein with anti-angiogenesis effect in retina via eye drops

Dichloroacetate ameliorates apoptosis, EMT and oxidative stress in diabetic cataract via inhibiting the IDO1-dependent p38 MAPK pathway

Systemic Anti-Inflammatory Therapy Aided by Curcumin-Laden Double-Headed Nanoparticles Combined with Injectable Long-Acting Insulin in a Rodent Model of Diabetes Eye Disease

Mitigation of lens opacification by a functional food in a diabetic rodent model

Evaluating the Efficacy of Polyglycolic Acid-Loading Tetrandrine Nanoparticles in the Treatment of Dry Eye

Cyclic RGD Conjugated PEG-PLGA Nanoparticle Enhances Preventative Effect of Bilirubin on the Development of Ultraviolet-B (Uvb)-Induced Cataract

Gold Nanoparticles Encapsulated Resveratrol as an Anti-Aging Agent to Delay Cataract Development

Nitro Dihydrocapsaicin, a Non-Pungent Capsaicin Analogue, Inhibits Cellular Senescence of Lens Epithelial Cells via Upregulation of SIRT1

Ophthalmic Drops with Nanoparticles Derived from a Natural Product for Treating Age-Related Macular Degeneration

Coenzyme Q10 eyedrops conjugated with vitamin E TPGS alleviate neurodegeneration and mitochondrial dysfunction in the diabetic mouse retina

Eyedrop delivery of therapeutic proteins with zwitterionic polymers to treat dry age-related macular degeneration

Synthesis and Biological Evaluation of Novel Gigantol Derivatives as Potential Agents in Prevention of Diabetic Cataract

Dual-ROS-scavenging and dual-lingering nanozyme-based eye drops alleviate dry eye disease

Therapeutic effect and mechanism of action of pterostilbene nano drugs in dry eye models

Anti-oxidative and mucin-compensating dual-functional nano eye drops for synergistic treatment of dry eye disease

The Synergistic Effects of Polyol Pathway-Induced Oxidative and Osmotic Stress in the Aetiology of Diabetic Cataracts